Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuo Hamamoto

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
The Oncologist|October 5, 2014
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study)Yasuo Hamamoto, Tatsuro Yamaguchi, Tomohiro Nishina, et al.
Digestion|December 6, 2025
Diagnostic Performance of Fecal Biomarkers and Their Correlation with Endoscopic Severity in Immune Checkpoint Inhibitor- Related ColitisRyo Morikawa, Toshimitsu Fujii, Akiko Tamura, et al.
Anticancer Research|September 21, 2012
Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cellsMotoko Izumiya, Ayano Kabashima, Hajime Higuchi, et al.
Japanese Journal of Clinical Oncology|September 10, 2013
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)Kuniaki Shirao, Narikazu Boku, Yasuhide Yamada, et al.
Japanese Journal of Clinical Oncology|February 3, 2016
Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 studyYasuo Hamamoto, Junki Mizusawa, Hiroshi Katayama, et al.
Japanese Journal of Clinical Oncology|December 20, 2015
Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology GroupYasuo Hamamoto, Yasunori Akutsu, Fumio Nagashima, et al.
Investigational New Drugs|March 25, 2018
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysisAkiyoshi Kasuga, Yasuo Hamamoto, Ayano Takeuchi, et al.
Future Oncology (London, England)|April 21, 2021
Analysis of risk factors for immune-related adverse events in various solid tumors using real-world dataKeitaro Shimozaki, Yasutaka Sukawa, Yasunori Sato, et al.
Journal of Gastroenterology|May 31, 2012
Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotypeHiromasa Takaishi, Takanori Kanai, Atsushi Nakazawa, et al.
Gastrointestinal Endoscopy|May 12, 2018
Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancerMasashi Takeuchi, Koichi Suda, Yasuo Hamamoto, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
The Oncologist|October 5, 2014
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study)Yasuo Hamamoto, Tatsuro Yamaguchi, Tomohiro Nishina, et al.
Digestion|December 6, 2025
Diagnostic Performance of Fecal Biomarkers and Their Correlation with Endoscopic Severity in Immune Checkpoint Inhibitor- Related ColitisRyo Morikawa, Toshimitsu Fujii, Akiko Tamura, et al.
Anticancer Research|September 21, 2012
Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cellsMotoko Izumiya, Ayano Kabashima, Hajime Higuchi, et al.
Japanese Journal of Clinical Oncology|September 10, 2013
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)Kuniaki Shirao, Narikazu Boku, Yasuhide Yamada, et al.
Japanese Journal of Clinical Oncology|February 3, 2016
Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 studyYasuo Hamamoto, Junki Mizusawa, Hiroshi Katayama, et al.
Japanese Journal of Clinical Oncology|December 20, 2015
Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology GroupYasuo Hamamoto, Yasunori Akutsu, Fumio Nagashima, et al.
Investigational New Drugs|March 25, 2018
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysisAkiyoshi Kasuga, Yasuo Hamamoto, Ayano Takeuchi, et al.
Future Oncology (London, England)|April 21, 2021
Analysis of risk factors for immune-related adverse events in various solid tumors using real-world dataKeitaro Shimozaki, Yasutaka Sukawa, Yasunori Sato, et al.
Journal of Gastroenterology|May 31, 2012
Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotypeHiromasa Takaishi, Takanori Kanai, Atsushi Nakazawa, et al.
Gastrointestinal Endoscopy|May 12, 2018
Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancerMasashi Takeuchi, Koichi Suda, Yasuo Hamamoto, et al.
Pageof 13